BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,946,159 | +4.7% | 73,802 | -32.5% | 0.00% | -33.3% |
| Q2 2023 | $1,858,706 | +40289.1% | 109,400 | -59.2% | 0.00% | -57.1% |
| Q1 2023 | $4,602 | +2361.0% | 268,300 | +995.1% | 0.01% | – |
| Q4 2022 | $187 | -99.9% | 24,500 | +72.5% | 0.00% | – |
| Q1 2022 | $147,000 | -83.7% | 14,200 | -77.1% | 0.00% | -100.0% |
| Q4 2021 | $904,000 | -49.6% | 62,100 | +64.7% | 0.00% | -50.0% |
| Q3 2021 | $1,795,000 | -16.4% | 37,700 | +5.6% | 0.00% | -33.3% |
| Q2 2021 | $2,146,000 | +144.1% | 35,700 | +140.0% | 0.00% | +200.0% |
| Q1 2021 | $879,000 | – | 14,878 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |